Specify a stock or a cryptocurrency in the search bar to get a summary
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
688076Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates. The company was founded in 2009 and is headquartered in Hangzhou, China. Address: Building E, Hangzhou, China, 311121
Analytics
WallStreet Target Price
636.46 CNYP/E ratio
27.5183Dividend Yield
0.93 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688076
Dividend Analytics 688076
Dividend growth over 5 years
–Continuous growth
1 yearPayout Ratio 5 years average
25 %Dividend History 688076
Stock Valuation 688076
Financials 688076
Results | 2019 | Dynamics |